Zymeworks $(ZYME)$ reported FY 2025 total revenue of USD 106.0 million, up 39%, and a FY net loss of USD 81.1 million, down 34%. In Q4 2025, revenue was USD 2.5 million and net loss was USD 41.2 million. FY 2025 R&D expenses were USD 137.0 million and G&A expenses were USD 61.5 million. Zymeworks ended 2025 with USD 270.6 million in cash, cash equivalents and marketable securities. On the business side, partner Jazz expects to complete a supplemental BLA for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma in Q1 2026 in the U.S., with a potential launch in H2 2026. Zymeworks said it is eligible for up to USD 440.0 million in regulatory milestones tied to Ziihera approvals in GEA across the U.S., Europe, Japan and China, and noted tiered royalties with Jazz and BeOne. The company also announced a USD 250.0 million non-recourse royalty-backed note financing with Royalty Pharma and said it had used USD 62.5 million of its USD 125.0 million share repurchase authorization as of March 2, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020600PRIMZONEFULLFEED9663681) on March 02, 2026, and is solely responsible for the information contained therein.